COMP <GO>
USPH vs LLY // FORWARD P/E MULTIPLE
U.S. Physical Therapy Inc. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: USPH 3
— LLY 10
▲ FORWARD P/E MULTIPLE LEADER: LLY
LAST: $86.57 (+1.47%) • MKT CAP: $1.29B
forward-pe
27.4x
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
forward-pe
26.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (USPH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | USPH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 19.20% | 83.64% | -64.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.50% | 32.36% | -20.86 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 16.3x | 36.4x | -20.12 | USPH | /valuation <GO> |
| Free Cash Flow Yield | 5.81% | 2.30% | +3.51 | USPH | /fcf-yield <GO> |
| Operating Margin | 11.10% | 40.21% | -29.11 | LLY | /operating-margins <GO> |
| Net Profit Margin | 5.10% | 31.90% | -26.80 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 16.30% | 45.51% | -29.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.12% | 0.49% | +1.63 | USPH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.94 | 9.29 | -6.35 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 66.6 | -14.35 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 27.4x | 26.3x | +1.15 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.29B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | USPH REV | LLY REV | USPH GROSS % | LLY GROSS % | USPH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $781.0M | $65.18B | 19.2% | 83.0% | $75.1M | $16.81B |
| FY 2024 | $671.3M | $45.04B | 18.5% | 81.3% | $74.9M | $8.82B |
| FY 2023 | $604.8M | $34.12B | — | 79.3% | $82.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
USPH // BETA —
LLY // BETA 0.51